Sales & Support: 314-485-5210



Catalogue number:
5 mg
Product is available in:
  • USA
  • Canada
$175.00 Shipping is calculated in checkout

PP1 is a selective and potent Src-family tyrosine kinase inhibitor. PP1 studies have proved its ability to potently inhibit Lck and Fyn (FynT), IL-2 gene activation in T lymphocytes, and anti-CD3-induced protein tyrosine phosphorylation. Research indicates that PP1 effectively blocks LPA and EGF-enhanced tyrosine phosphorylation, MAPK activation downstream of EGFR, Rsk-1 (p90RSK) activation by H2O2, Kit and Bcr-Abl tyrosine kinases, and degrades RETMEN2A and RETMEN2B oncoproteins via proteosomal targeting. PP1 and its analog, PP2, are powerful inhibitors of TGF-β-induced cell migration and invasion in-vitro. PP1 inhibits anti-CD3-induced T cell tyrosine phosphorylation, TcR-induced T cell proliferation, and IL-2 gene induction. PP1 has been demonstrated to reduce the expression of vascular endothelial growth factor (VEGF), protect the blood-brain barrier, reduce brain edema immediately after subarachnoid hemorrhage, and offer cerebral protection against stroke. It prevents metastatic spread in late-stage pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Product Type:

Peptides & proteins

CAS Number:


Alternative Names:

AGL-1872, PP 1, 1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine


1) Kingham, E. and Welham, M. 2009. J Cell Sci. 122:2311-2321. PMID: 19509054; 2) Yi, YW., et al. 2013. Mol Carcinog. 52(9): 667-675. PMID: 22488590; 3) Thomas, D., et al. 2013. Blood. 122(5): 738-748. PMID: 23775716

Limit of Detection:


Storage Temperature:

-20°C. Keep away from direct sunlight.

Shelf Life:

12 months from receipt